Roth Capital Downgrades Salix Pharmaceuticals Ltd. (SLXP) to Hold
More News related to SLXP
- Salix Pharmaceuticals (SLXP) Receives Complete Response Letter From FDA for Balsalazide Tablet; Reaffirms FY08 Outlook
- Salix Receives FDA Complete Response Letter for Balsalazide Tablet
- Salix Pharmaceuticals Announces New Online Resource Site to Educate Healthcare Providers on Proper Use of Prescription Bowel Cleansing Preparations
- FDA Says Salix Phama (SLXP) Bowel-Cleansing Drugs May Be Linked to Kidney Injury
- Salix In-Licenses Crofelemer from Napo Pharmaceuticals
More News related to Downgrades
- ARGUS Downgrades Smith International (SII) to Hold
- Cantor Fitzgerald Downgrades Audiocodes (AUDC) to Hold After Negative 4Q Preannouncement
- MDB Capital Downgrades Ener1 (HEV) to Sell, Suspends Earnings Model and Valuation on Stock No Longer Justified
- DA Davidson Downgrades Ambassadors Group (EPAX) to Neutral
- SunTrust Downgrades Ruby Tuesday, Inc. (RT) to Neutral
Roth Capital downgrades Salix Pharmaceuticals Ltd. (Nasdaq: SLXP) from Buy to Hold with an $8 price target.
Salix Pharmaceuticals, Ltd. develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases in the United States.
Related Categories
DowngradesStocks Mentioned
+0.19Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
